Moderna stock (US60770K1079): Shares up 71% YTD amid biotech volatility

Moderna's stock has surged 71% since the start of 2026, trading at $50.42 on Nasdaq after a 5.35% daily drop. Recent earnings beat expectations, but analyst targets suggest potential downside.

Moderna stock experienced a sharp 5.35% decline, closing at $50.42 USD on Nasdaq on May 13, 2026, according to MarketBeat as of 05/13/2026. Despite the pullback, shares have risen 71% year-to-date from $29.49 at the beginning of 2026. In its last quarterly earnings, Moderna reported EPS of -$1.18, surpassing the Zacks Consensus Estimate of -$3.02, per Zacks as of 07/08/2025.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Moderna Inc
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: Global, with strong US focus
• Key revenue drivers: mRNA vaccines and therapeutics
• Home exchange/listing venue: Nasdaq (MRNA)
• Trading currency: USD

Moderna: core business model

Moderna Inc develops and commercializes mRNA-based medicines and vaccines. The company gained prominence during the COVID-19 pandemic with its Spikevax vaccine, co-developed with the US government. Today, Moderna focuses on a pipeline including respiratory vaccines, cancer therapies, and rare disease treatments, leveraging its mRNA platform for rapid development.

Headquartered in Cambridge, Massachusetts, Moderna operates globally but maintains significant exposure to the US market through government contracts and clinical trials. Its business model emphasizes proprietary mRNA technology, with manufacturing scaled via partnerships and internal facilities.

Main revenue and product drivers for Moderna

Spikevax remains Moderna's primary revenue source, though sales have declined post-pandemic. The company reported strong earnings beats in recent quarters, such as the EPS of -$1.18 versus a consensus of -$3.02 for the last period published prior to July 2025, according to Zacks as of 07/08/2025. Pipeline candidates like mRNA-1345 for RSV and individualized neoantigen therapies drive future growth expectations.

Moderna's US relevance stems from its role in national health security, with substantial NIH and BARDA funding. Revenue is predominantly from vaccines, with oncology and latent virus programs expanding diversification.

Industry trends and competitive position

The biotech sector faces volatility from patent cliffs and funding shifts, but mRNA technology positions Moderna as a leader. Competitors like Pfizer-BioNTech and BioNTech challenge in vaccines, while oncology rivals include emerging cell therapy firms. Moderna's edge lies in its end-to-end mRNA platform, enabling faster iterations than traditional biotech.

Why Moderna matters for US investors

Listed on Nasdaq, Moderna offers US investors direct exposure to innovative biotech with heavy government backing. Its products address US public health priorities like pandemics and cancer, influencing sector ETFs and retirement portfolios focused on healthcare innovation.

Conclusion

Moderna stock has shown remarkable YTD gains amid biotech sector dynamics, supported by earnings outperformance and a robust mRNA pipeline. While recent price action reflects volatility, the company's US-centric operations and innovation focus continue to draw investor attention. Market conditions and pipeline milestones will shape near-term performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.